Fox Run Management’s TherapeuticsMD TXMD Stock Holding History

Fox Run Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-453	Closed	-$149K	–	736
2018 Q3	$149K	Buy	453 +66	+17%	+$20.2K	0.07%	501
2018 Q2	$121K	Buy	+387	New	+$118K	0.04%	623
2018 Q1	–	Sell	-229	Closed	-$69K	–	931
2017 Q4	$69K	Buy	+229	New	+$63.7K	0.02%	630

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Fox Run Management's TXMD Position: Q4 2018 in Review

Fox Run Management sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 453 shares — an estimated $149K sold.

Fox Run Management first reported a position in TXMD in Q4 2017 and held it in 3 quarters. The position peaked at $149K in Q3 2018. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Fox Run Management reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Fox Run Management sold 453 TherapeuticsMD shares in Q4 2018, an estimated $149K.
Fox Run Management first reported a position in TherapeuticsMD in Q4 2017 and held it in 3 quarters.
Fox Run Management's TherapeuticsMD position peaked at $149K in Q3 2018.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Fox Run Management's 13F filing for Q4 2018, filed 15 Jan 2019.